我們已在上線！進一步了解

SGEN

Seagen Inc. Common Stock

SGEN

市值 US$432億

已下市

SGEN已於2023年12月13日下市。

返回排名列表

關於： Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

員工： 3,256

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 0%

負面 0%

How Pfizer's $43B acquisition of Seagen may impact Seattle and broader biotech market

Editor's note: William Canestaro is managing director at Seattle venture capital firm WRF Capital and leads the biotechnology investment team.

Proactive Investors

Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen

Pfizer Inc (NYSE:PFE) said today that it is expecting $58.5 billion to $61.5 billion of sales in 2024 from Covid-19 vaccines, antiviral medicine Paxlovid and Seagen, with deal for the latter cancer drug company imminent. This is higher than its legacy 2024 guidance and slightly above the guidance it gave in October for 2023 sales.

Investors Business Daily

Pfizer's Tumble Steepens As Seagen Guidance Update Disappoints

Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target.

Pfizer wins regulatory approval for its $43B acquisition of Seattle-area biotech giant Seagen

Pfizer's plan to acquire Seagen for $43 billion has cleared the necessary regulatory hurdles, the pharma titan announced Tuesday.

8 Tax-Loss Sell Alerts For December

Investors should consider tax-loss selling before December ends to offset capital gains. Two characteristics to consider for selling stocks are stocks bought at a higher price and broken companies with weak long-term prospects. Stock grades, sentiment, and fundamentals assessed.

Proactive Investors

Pfizer to close Seagen acquisition after donating cancer drug rights

Pfizer Inc (NYSE:PFE) announced on Tuesday that it will donate the rights of royalties from sales of cancer drug Bavencio to the American Association for Cancer Research (AACR) in order to address concerns from US antitrust regulators related to its pending $43-billion acquisition of Seagen Inc. The big US drugmaker said it now expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions. Pfizer noted the waiting period for the Federal Trade Commission to oppose the acquisition expired on Monday.

Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

Pfizer said on Tuesday it has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy Seagen.

Pfizer expects to close Seagen deal on Thursday, will create a new oncology division to incorporate company

Pfizer Inc. PFE, -0.49% said Tuesday it has received all the regulatory approvals needed to close the acquisition of Seagen Inc. SGEN, +1.20% and expects to close the deal on Thursday. To address concerns raised by the Federal Trade Commission, the drug company has agreed to donate the rights of royalties from sales of Bavencio in the U.S. to the American Association for Cancer Research to support it in its mission of curing cancer through research and funding.

Pfizer expects to close Seagen deal on Thursday, will create a new oncology division to incorporate company

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ: SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition. Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing con.

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

BOTHELL, Wash.--(BUSINESS WIRE)-- #ASH23--Seagen Inc. (NASDAQ: SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate (ADC) ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) as first-line treatment for early and advanced stage classical Hodgkin lymphoma (cHL). This is the first time 12-m.

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

查看新聞排名

價格圖表採用Lightweight Charts™實作